Moderate to severe HS can be progressive and debilitating.2-5 The severity of HS may be determined by the Hurley staging system, a widely used classification.6
Typically presents as abscess formation, single or multiple, without sinus tracts and scarring
Hurley Stages II and III studied in PIONEER pivotal trials
Typically presents as recurrent abscesses with sinus tract formation and scarring; single or multiple widely separated lesions
Typically presents as diffuse or near-diffuse involvement with multiple interconnected sinus tracts and abscesses across entire area
Adapted with permission from Jemec, 2012.6
HS is a chronic, debilitating immune-mediated disease that manifests on the skin, occurring in many patients’ most sensitive areas.2,3,7 Typical signs and symptoms of moderate to severe HS lesions include7:
Multiple nodules and abscesses
Inflammation in the dermis
Scarring, ulceration, and infection
PRESENTATION OF HS LESIONS IN WOMEN AND MEN
Recurring lesions commonly affect these sensitive areas in women and men.3,8 Symptoms can start at any time between puberty and middle age—one study states the average age of onset is 21.5
“As you can imagine, this disease can make sitting uncomfortable when I have several large lesions around my inner thighs and buttocks.”
“The patient was [Hurley stage II/III and in need of some] relief from this condition.... While the family physician was not comfortable prescribing an injectable biologic medication, he offered the patient a referral to dermatology.”
– Insight from a physician, The Journal of Family Practice, 2015.9
PREVALENCE OF HS
HS is relatively rare. The prevalence of all forms of HS reported in published literature varies. It is estimated that the number of adults in the U.S. living with the moderate to severe form of HS is between 115,000 and 189,000.10
Females are more likely than males to develop HS, with a 3:1 ratio.11
But HS may be more common than you think, as it is often misdiagnosed, or goes undiagnosed for years when hidden by embarrassed patients.3,8 From an AbbVie conducted market research survey, patients with HS on average see 5 doctors over 8 years before they are properly diagnosed.12
RISK FACTORS TO CONSIDER
The development of HS depends on a combination of factors. However, it may be helpful to know that the data on patients with HS has some patterns to help you recognize this often overlooked disease.
GENETIC FACTORS: 30%-40% of patients with HS have at least one family member who has it as well13
HORMONAL FACTORS: A strong relationship exists between HS and sex hormones, as demonstrated by the onset after puberty, and lack of onset after menopause14
MECHANICAL FACTORS: Weak structural support at the junction of the sebaceous gland and the follicular duct likely predisposes to follicular rupture caused by local trauma14
OBESITY may exacerbate HS symptoms, with higher body mass index associated with increased disease severity15
SMOKING can promote follicular plugging, which may contribute to the pathogenesis of HS14
COMORBIDITIES such as Crohn's disease or spondyloarthropathy often may be present in patients with HS14
“The swelling, the discharge—I know this is an incurable disease, but is it wrong for me to hope for something that can help my lesions?”
– Insight from actual HS female patient
By clicking this link, you’ll be leaving hspartnership.com and going to a website not sponsored by AbbVie.
Is this what you would like to do?
You are about to enter a site that is for U.S. Healthcare Professionals Only.
By selecting “Yes” below, you certify that you are a Healthcare Professional and that you wish to proceed to the Healthcare Professionals Only section on the AbbVie Medical Information site. Products or treatments described on this site are available in the U.S. but may not be available in all other countries. I am a licensed Healthcare Professional and wish to proceed to the Healthcare Professionals Only AbbVie Medical Information Site.
Terms and Conditions
AbbVie is providing this service to help patients find dermatologists in their area who have experience with HUMIRA.
No fees have been received by or paid to dermatologists for inclusion in this specialist locator directory. Inclusion of a physician in this directory does not represent an endorsement by or a recommendation from AbbVie Inc., nor does it imply that the dermatologists on the list will determine if HUMIRA is right for you.
The selection of a physician is an important decision that should not be based solely on the inclusion in this dermatologist locator tool.
AbbVie Inc. is a maker and marketer of HUMIRA (adalimumab).